Alnylam to Webcast Presentations at Upcoming March Investor Conferences

Rhea-AI Summary

Alnylam Pharmaceuticals (Nasdaq: ALNY) will present company overviews at two upcoming conferences: the Cowen 42nd Annual Healthcare Conference on March 8, 2022, at 9:50 am ET, and the Barclays Global Healthcare Conference on March 15, 2022, at 8:00 am ET in Miami, Florida. Live audio webcasts will be accessible on the Investor section of Alnylam's website, with replays available within 48 hours post-event. Alnylam specializes in RNA interference therapeutics, aiming to transform treatment for rare and prevalent diseases.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:

• Cowen 42^nd Annual Healthcare Conference on Tuesday, March 8, 2022 at 9:50 am ET, being held virtually
• Barclays Global Healthcare Conference on Tuesday, March 15, 2022 at 8:00 am ET at the Loews Miami Beach Hotel in Miami, Florida

A live audio webcast of each presentation will be available on the Investors section of the Company’s website at www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after each event.

About Alnylam

Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO^® (patisiran), GIVLAARI^® (givosiran), OXLUMO^® (lumasiran) and Leqvio^® (inclisiran) being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P⁵x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220228005632/en/

Alnylam Pharmaceuticals, Inc.

Christine Regan Lindenboom

(Investors and Media)

617-682-4340

Josh Brodsky

(Investors)

617-551-8276

Source: Alnylam Pharmaceuticals, Inc.

FAQ

When will Alnylam Pharmaceuticals present at the Cowen Healthcare Conference?

Alnylam Pharmaceuticals will present at the Cowen 42nd Annual Healthcare Conference on March 8, 2022, at 9:50 am ET.

Where will Alnylam Pharmaceuticals present on March 15, 2022?

Alnylam Pharmaceuticals will present at the Barclays Global Healthcare Conference on March 15, 2022, at 8:00 am ET at Loews Miami Beach Hotel in Miami, Florida.

Will there be a live stream for Alnylam Pharmaceuticals' presentations?

Yes, live audio webcasts of Alnylam Pharmaceuticals' presentations will be available on the Investors section of their website.

How soon will replays of Alnylam Pharmaceuticals' presentations be available?

Replays of Alnylam Pharmaceuticals' presentations will be available within 48 hours after each event.

What is the focus of Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals specializes in RNA interference (RNAi) therapeutics, focusing on innovative medicines for rare and prevalent diseases.